— First devices shipped to Greece
— Mentetech website streamlined and highlighting vision
Perth, Australia & Malta – 25 May 2017 – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions in the neuroscience space, has reached another milestone with the first shipment of Mente Autism devices to Greece.
The initial shipment of devices was completed and payment received this week.
Delivery of the first Mente Autism units to Greece comes after the recent appointment of Greek medical devices specialist Bonvie Group as distribution partner for Greece and Cyprus.
Training of the local distributor’s sales teams and medical experts has commenced and is ongoing, with various marketing initiatives under way.
“This is another important milestone for the Company as we continue to increase our international reach and enter new markets. We will be exploring new commercial avenues with our distribution partner, Bonvie, to maintain momentum with increased orders in the coming months,” Neurotech’s CEO Wolfgang Storf said.
UPDATED MENTETECH WEBSITE
Neurotech has completed an update to the Mentetech product website (www.mentetech.com) to emphasise the vision of Mente Autism, “Bridging to a Better Life”, and for more streamlined navigation.
The updated website provides more streamlined navigation and highlights the four key pillars of Mente Autism for parents and carers of children with Autism Spectrum Disorder (ASD), being Affordability, Belonging, Convenience and Control.
“Our vision for Mente Autism is to help parents and carers of children with ASD lead a better life. Mente helps children with ASD to relax their minds but it goes beyond positive behavioural or communication changes. We see Mente Autism as a unique therapy that bridges the gap between the isolated environment they live in and a society that often struggles to understand and accept them. Mente Autism helps both parents and their child to integrate, and be accepted in society, thus improving their quality of life,” Mr Storf said.
“We are conscious of the fact that parents do not have it easy. They face financial pressures and have to balance this with family life and bringing up their child. Mente Autism addresses these through offering an affordable product, providing a therapy and medical device that they can use in the comfort and convenience of their home, and empowering them to monitor progress on their own along with their medical professional of choice. The Mentetech website is an important tool of communicating with the parents and carers of our end users, and the update is key to ensuring that we are able to effectively engage with them with a more user friendly interface.”
For more information please contact:
Matthew Wright
matt@nwrcommunications.com.au
Tel: +61 451 896 420
About Neurotech
Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. For more information, visit: http://www.neurotechinternational.com
